Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Adv Respir Med ; 91(4): 288-300, 2023 Jul 04.
Artículo en Inglés | MEDLINE | ID: mdl-37489386

RESUMEN

Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting ß2-agonists (ICS + LABA) (closed triple inhaler therapy) or in a separate one (open triple inhaler therapy). This review summarizes the existing evidence on the addition of LAMAs in patients with persistently uncontrolled asthma despite ICS + LABA treatment based on clinical efficacy in the reduction of asthma symptoms and exacerbations, the improvement in lung function, and its safety profile.


Asunto(s)
Agonistas de Receptores Adrenérgicos beta 2 , Asma , Humanos , Agonistas de Receptores Adrenérgicos beta 2/uso terapéutico , Administración por Inhalación , Quimioterapia Combinada , Asma/tratamiento farmacológico , Nebulizadores y Vaporizadores , Antagonistas Muscarínicos/uso terapéutico , Corticoesteroides/uso terapéutico
2.
Ann Ital Chir ; 93: 592-598, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36254771

RESUMEN

AIM: Our goal was to investigate the potential use and efficacy of regorafenib for IPEC in an animal model of colorectal derived peritoneal metastases. Twenty four male rats were included. Carcinogenesis was induced in all rats through intraperitoneal injection of cancer. MATERIAL AND METHODS: Cells at T0. At T1(Day 28) they were randomly allocated 1:1:1:1 into 4 groups and underwent median laparotomy and the corresponding intervention. Specifically, Group A: no other intervention; Group B: cytoreductive surgery; Group C: intraperitoneal chemotherapy with regorafenib; and Group D: cytoreductive surgery and intraperitoneal chemotherapy with regorafenib. At T2 (Day 56) rats were euthanized and laparotomy was performed for further investigation. The primary outcome was the experimental Peritoneal Cancer Index (ePCI) at T2. Secondary outcomes include relative change of body weight between T1 and T2, weight of the ascites, anastomotic leak/peritonitis and death. RESULTS: The ePCI was significantly lower in Group D as opposed to all other groups. Comparing Group C versus Group A we found a trend towards lesser tumor progression, but no significant difference. Growth of rats in Group D was significantly least affected compared to all other groups. Animals undergoing CRS in Group B developed less ascites than Group A and C. Less ascites was found in Group D compared to Group A and C. CONCLUSIONS: Intraperitoneal chemotherapy with regorafenib combined with cytoreductive surgery may impair metastases' progression. KEY WORDS: Regorafenib, Chemotherapy, Cytoreductive surgery, Colorectal cancer, Intraperitoneal injection.


Asunto(s)
Neoplasias Colorrectales , Hipertermia Inducida , Neoplasias Peritoneales , Animales , Protocolos de Quimioterapia Combinada Antineoplásica , Ascitis , Neoplasias Colorrectales/patología , Terapia Combinada , Procedimientos Quirúrgicos de Citorreducción , Estudios de Factibilidad , Inyecciones Intraperitoneales , Masculino , Neoplasias Peritoneales/patología , Compuestos de Fenilurea , Piridinas , Ratas , Tasa de Supervivencia
3.
Drug Des Devel Ther ; 7: 1003-13, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24082782

RESUMEN

Humans have the ability to synthesize vitamin D during the action of ultraviolet (UV) radiation upon the skin. Apart from the regulation of calcium and phosphate metabolism, another critical role for vitamin D in immunity and respiratory health has been revealed, since vitamin D receptors have also been found in other body cells. The term "vitamin D insufficiency" has been used to describe low levels of serum 25-hydroxyvitamin D that may be associated with a wide range of pulmonary diseases, including viral and bacterial respiratory infection, asthma, chronic obstructive pulmonary disease, and cancer. This review focuses on the controversial relationship between vitamin D and asthma. Also, it has been found that different gene polymorphisms of the vitamin D receptor have variable associations with asthma. Other studies investigated the vitamin D receptor signaling pathway in vitro or in experimental animal models and showed either a beneficial or a negative effect of vitamin D in asthma. Furthermore, a range of epidemiological studies has also suggested that vitamin D insufficiency is associated with low lung function. In the future, clinical trials in different asthmatic groups, such as infants, children of school age, and ethnic minorities are needed to establish the role of vitamin D supplementation to prevent and/or treat asthma.


Asunto(s)
Asma/fisiopatología , Receptores de Calcitriol/metabolismo , Vitamina D/metabolismo , Animales , Asma/tratamiento farmacológico , Asma/etiología , Niño , Suplementos Dietéticos , Humanos , Lactante , Polimorfismo Genético , Receptores de Calcitriol/genética , Transducción de Señal , Vitamina D/administración & dosificación , Deficiencia de Vitamina D/complicaciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA